Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:administeredBy |
oral
|
| gptkbp:alternativeName |
gptkb:tofacitinib
|
| gptkbp:approvalYear |
2012
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L04AA29
|
| gptkbp:CASNumber |
540737-29-9
|
| gptkbp:developedBy |
gptkb:Pfizer
|
| gptkbp:hasMolecularFormula |
C16H20N6O
|
| gptkbp:hasSMILES |
CC1=NC(=CN=C1N)N(C)CC2=NC=CC(=N2)N
|
| gptkbp:hasUNII |
FFL0D5469V
|
| https://www.w3.org/2000/01/rdf-schema#label |
CP-690550
|
| gptkbp:IUPACName |
3-[(3R,4R)-4-methyl-3-(methylamino)piperidin-1-yl]-3-oxopropanenitrile
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
Janus kinase inhibitor
|
| gptkbp:molecularWeight |
312.37 g/mol
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:PubChem_CID |
9926791
CHEMBL385360 DB08895 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
diarrhea
headache hypertension infections |
| gptkbp:target |
gptkb:JAK1
gptkb:JAK3 |
| gptkbp:usedFor |
gptkb:psoriatic_arthritis
ulcerative colitis rheumatoid arthritis |
| gptkbp:bfsParent |
gptkb:JAK3
|
| gptkbp:bfsLayer |
7
|